Title: HOUSE BILL 813
Official Title: HOUSE BILL 813
Number of Sections: 1
Source: versions - Third - Maryland Insurance Administration and Maryland Department of Health - Workgroup to Study Pharmacy Benefits Managers
Media Type: application/pdf
Strikethrough Detection: 5 sections found

================================================================================

Section 1:
J5 EMERGENCY BILL 5lr2785
HB 880/24 – HGO CF SB 438
By: Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall, Bhandari,
Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez, Martinez,
M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga, Taveras,
White Holland, Woods, and Woorman
Introduced and read first time: January 29, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable with amendments
House action: Adopted
Read second time: March 1, 2025
CHAPTER ______
1 AN ACT concerning
2 Pharmacy Benefits Administration – Maryland Medical Assistance Program and
3 Pharmacy Benefits Managers
4 Maryland Insurance Administration and Maryland Department of Health –
5 Workgroup to Study Pharmacy Benefits Managers
6 FOR the purpose of altering the reimbursement levels for drug products that the Maryland
7 Medical Assistance Program is required to establish and that pharmacy benefits
8 managers that contract with a pharmacy on behalf of a managed care organization
9 are required to reimburse the pharmacy; altering the definition of “purchaser” for
10 purposes of certain provisions of law regulating pharmacy benefits managers to
11 include certain insurers, nonprofit health service plans, and health maintenance
12 organizations requiring the Maryland Insurance Administration and the Maryland
13 Department of Health to convene a workgroup to study certain issues related to
14 pharmacy benefits managers and report to certain committees on or before a certain
15 date; and generally relating to pharmacy benefits administration a workgroup to
16 study pharmacy benefits managers.
17 BY repealing and reenacting, with amendments,
18 Article – Health – General
19 Section 15–118(b)
20 Annotated Code of Maryland
21 (2023 Replacement Volume and 2024 Supplement)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb0813*
2 HOUSE BILL 813
1 BY adding to
2 Article – Health – General
3 Section 15–118(f)
4 Annotated Code of Maryland
5 (2023 Replacement Volume and 2024 Supplement)
6 BY repealing and reenacting, with amendments,
7 Article – Insurance
8 Section 15–1601(s)
9 Annotated Code of Maryland
10 (2017 Replacement Volume and 2024 Supplement)
11 BY adding to
12 Article – Insurance
13 Section 15–1632
14 Annotated Code of Maryland
15 (2017 Replacement Volume and 2024 Supplement)
16 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
17 That the Laws of Maryland read as follows:
18 Article – Health – General
19 15–118.
20 (b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION AND
21 EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall
22 establish [maximum] MINIMUM reimbursement levels for the drug products for which
23 there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[,
24 based on the cost of the generic product].
25 (2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION,
26 MINIMUM REIMBURSEMENT LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
27 SUBSECTION SHALL BE AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG
28 ACQUISITION COST OF THE GENERIC PRODUCT PLUS THE FEE–FOR–SERVICE
29 PROFESSIONAL DISPENSING FEE DETERMINED BY THE DEPARTMENT IN
30 ACCORDANCE WITH THE MOST RECENT IN–STATE COST–OF–DISPENSING SURVEY.
31 [(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS
32 SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level
33 shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the
34 brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE
35 DETERMINED BY THE DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT
36 IN–STATE COST–OF–DISPENSING SURVEY.
HOUSE BILL 813 3
1 (4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION DO NOT APPLY TO:
2 (I) A PHARMACY OWNED BY OR UNDER THE SAME CORPORATE
3 AFFILIATION AS A PHARMACY BENEFITS MANAGER; OR
4 (II) A MAIL ORDER PHARMACY.
5 (F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO
6 A MANAGED CARE ORGANIZATION THAT USES A PHARMACY BENEFITS MANAGER TO
7 MANAGE PRESCRIPTION DRUG COVERAGE BENEFITS ON BEHALF OF THE MANAGED
8 CARE ORGANIZATION.
9 Article – Insurance
10 15–1601.
11 (s) (1) “Purchaser” means a person that offers a plan or program in the State,
12 including the State Employee and Retiree Health and Welfare Benefits Program, AN
13 INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE
14 ORGANIZATION, that:
15 [(1)] (I) provides prescription drug coverage or benefits in the State; and
16 [(2)] (II) enters into an agreement with a pharmacy benefits manager for
17 the provision of pharmacy benefits management services.
18 (2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH
19 MAINTENANCE ORGANIZATION THAT:
20 (I) OPERATES AS A GROUP MODEL;
21 (II) PROVIDES SERVICES SOLELY TO A MEMBER OR PATIENT OF
22 THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND
23 (III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY
24 OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
25 15–1632.
26 A PHARMACY BENEFITS MANAGER THAT CONTRACTS WITH A PHARMACY ON
27 BEHALF OF A MANAGED CARE ORGANIZATION, AS DEFINED IN § 15–101 OF THE
28 HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT
29 THAT IS AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST
30 PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
31 MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE
4 HOUSE BILL 813
1 PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN–STATE
2 COST–OF–DISPENSING SURVEY.
3 SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
4 measure, is necessary for the immediate preservation of the public health or safety, has
5 been passed by a yea and nay vote supported by three–fifths of all the members elected to
6 each of the two Houses of the General Assembly, and shall take effect from the date it is
7 enacted.
8 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
9 That the Maryland Insurance Administration and the Maryland Department of Health
10 shall:
11 (1) convene a workgroup of interested stakeholders, including community
12 pharmacies from both chain and independent settings, pharmacy services administrative
13 organizations, pharmacists, pharmacy benefits managers, and managed care organizations
14 and third–party experts in the field of drug pricing in Medicaid;
15 (2) review reimbursement for pharmacists, including:
16 (i) existing Maryland Medical Assistance Program requirements for
17 pharmacy benefits managers and managed care organizations related to dispensing fee
18 reimbursement, pharmacy benefits managers fees charged to pharmacies and the
19 Maryland Medical Assistance Program, transparency in pricing and reimbursement data,
20 specialty drug designations, and appeals processes;
21 (ii) how other states’ pharmacy benefits services operate in
22 Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;
23 (iii) measures that offset the Department’s costs to fund the Medicaid
24 Managed Care Program and adopt NADAC plus the Fee–for–Service Professional
25 Dispensing, including:
26 1. savings associated with NADAC ingredient cost pricing
27 and managed care organizations; and
28 2. pharmacy benefits managers administrative fee
29 consolidation and rebate allocations; and
30 (iv) strategies for adopting pharmacy reimbursement parity and
31 drug pricing transparency;
32 (3) review coverage requirements for specialty drugs, including:
33 (i) which drugs are considered specialty for purposes of formularies
34 across carriers and pharmacy benefits managers; and
HOUSE BILL 813 5
1 (ii) what these drugs have in common for purposes of developing a
2 new definition for “specialty drug”;
3 (4) review ERISA exemptions for pharmacy benefits management
4 regulation, including:
5 (i) the scope of Rutledge v. Pharmaceutical Care Management
6 Association and subsequent case law and federal guidance;
7 (ii) how other states have responded to the Rutledge decision; and
8 (iii) what, if any, other State laws should be amended;
9 (5) on or before December 31, 2025, submit an interim report on their
10 findings and recommendations to the Senate Finance Committee and the House Health
11 and Government Operations Committee, in accordance with § 2–1257 of the State
12 Government Article; and
13 (6) on or before December 31, 2026, submit a final report on their findings
14 and recommendations to the Senate Finance Committee and the House Health and
15 Government Operations Committee, in accordance with § 2–1257 of the State Government
16 Article.
17 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
18 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.
[DELETED: :CA    E 5   C P R R R S T A P P M W F M m a p o c p o l r p b m t i o D p d s B  A S  A  (]
[DELETED:  H  B  A S  A  ( B  A S  A  ( B  A S  A  (  S T A 1  ( ( Et ]S(  T  a p u p () o t s t P s]( e mmr l f t d p f w te, bt.    E()      S B A L E T T A V RA C– O O T G PTP T FEFRS   D F D B T E I NTTOFDS––    () If ]()[]E(X A P I P  O TN    s b b o t ct o t]NADAA V R C O b EFRS B T E I A W T M RNTTOFDS– .]
[DELETED: H 3    P()()        )  R      ) AI    )T§12IH    N R   . A 1  (  “ i t S E a R H a W B P,AR A N H S PN O A H M      () p] (   () e] ( t    “PR D N I A N H     ) O    )IPN      )IF     O A M C ON A D I   O T§1 –GA  E RE S R T P A A  A V R C OADA EFRS DHMM E E A E S ]
[DELETED:  H –S I A W T M R INTTOFD–   S m b e e  S T M s   ( c p o a   ( r    ( e p r p b m f c t p a t M s    ( h o s p b s o i M    ( m M C P a a N p t F P D     1 s a w N i c p a     2 p b m a f c    ( s f a p r p a d   ( r    ( w a]
[DELETED: H 5    ( w n   ( r E e f p b m r    ( t s o R v P C M A    ( h    ( w   ( o o b D 3 2 s a i r o t f a G O C i a w § 2 o t S G   ( o a r t t S F C a t H H a G A  S 1          G               ]


================================================================================

Raw Text:
HOUSE BILL 813
J5 EMERGENCY BILL 5lr2785
HB 880/24 – HGO CF SB 438
By: Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall, Bhandari,
Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez, Martinez,
M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga, Taveras,
White Holland, Woods, and Woorman
Introduced and read first time: January 29, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable with amendments
House action: Adopted
Read second time: March 1, 2025
CHAPTER ______
1 AN ACT concerning
2 Pharmacy Benefits Administration – Maryland Medical Assistance Program and
3 Pharmacy Benefits Managers
4 Maryland Insurance Administration and Maryland Department of Health –
5 Workgroup to Study Pharmacy Benefits Managers
6 FOR the purpose of altering the reimbursement levels for drug products that the Maryland
7 Medical Assistance Program is required to establish and that pharmacy benefits
8 managers that contract with a pharmacy on behalf of a managed care organization
9 are required to reimburse the pharmacy; altering the definition of “purchaser” for
10 purposes of certain provisions of law regulating pharmacy benefits managers to
11 include certain insurers, nonprofit health service plans, and health maintenance
12 organizations requiring the Maryland Insurance Administration and the Maryland
13 Department of Health to convene a workgroup to study certain issues related to
14 pharmacy benefits managers and report to certain committees on or before a certain
15 date; and generally relating to pharmacy benefits administration a workgroup to
16 study pharmacy benefits managers.
17 BY repealing and reenacting, with amendments,
18 Article – Health – General
19 Section 15–118(b)
20 Annotated Code of Maryland
21 (2023 Replacement Volume and 2024 Supplement)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb0813*

2 HOUSE BILL 813
1 BY adding to
2 Article – Health – General
3 Section 15–118(f)
4 Annotated Code of Maryland
5 (2023 Replacement Volume and 2024 Supplement)
6 BY repealing and reenacting, with amendments,
7 Article – Insurance
8 Section 15–1601(s)
9 Annotated Code of Maryland
10 (2017 Replacement Volume and 2024 Supplement)
11 BY adding to
12 Article – Insurance
13 Section 15–1632
14 Annotated Code of Maryland
15 (2017 Replacement Volume and 2024 Supplement)
16 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
17 That the Laws of Maryland read as follows:
18 Article – Health – General
19 15–118.
20 (b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION AND
21 EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall
22 establish [maximum] MINIMUM reimbursement levels for the drug products for which
23 there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[,
24 based on the cost of the generic product].
25 (2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION,
26 MINIMUM REIMBURSEMENT LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
27 SUBSECTION SHALL BE AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG
28 ACQUISITION COST OF THE GENERIC PRODUCT PLUS THE FEE–FOR–SERVICE
29 PROFESSIONAL DISPENSING FEE DETERMINED BY THE DEPARTMENT IN
30 ACCORDANCE WITH THE MOST RECENT IN–STATE COST–OF–DISPENSING SURVEY.
31 [(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS
32 SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level
33 shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the
34 brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE
35 DETERMINED BY THE DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT
36 IN–STATE COST–OF–DISPENSING SURVEY.

HOUSE BILL 813 3
1 (4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION DO NOT APPLY TO:
2 (I) A PHARMACY OWNED BY OR UNDER THE SAME CORPORATE
3 AFFILIATION AS A PHARMACY BENEFITS MANAGER; OR
4 (II) A MAIL ORDER PHARMACY.
5 (F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO
6 A MANAGED CARE ORGANIZATION THAT USES A PHARMACY BENEFITS MANAGER TO
7 MANAGE PRESCRIPTION DRUG COVERAGE BENEFITS ON BEHALF OF THE MANAGED
8 CARE ORGANIZATION.
9 Article – Insurance
10 15–1601.
11 (s) (1) “Purchaser” means a person that offers a plan or program in the State,
12 including the State Employee and Retiree Health and Welfare Benefits Program, AN
13 INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE
14 ORGANIZATION, that:
15 [(1)] (I) provides prescription drug coverage or benefits in the State; and
16 [(2)] (II) enters into an agreement with a pharmacy benefits manager for
17 the provision of pharmacy benefits management services.
18 (2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH
19 MAINTENANCE ORGANIZATION THAT:
20 (I) OPERATES AS A GROUP MODEL;
21 (II) PROVIDES SERVICES SOLELY TO A MEMBER OR PATIENT OF
22 THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND
23 (III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY
24 OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
25 15–1632.
26 A PHARMACY BENEFITS MANAGER THAT CONTRACTS WITH A PHARMACY ON
27 BEHALF OF A MANAGED CARE ORGANIZATION, AS DEFINED IN § 15–101 OF THE
28 HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT
29 THAT IS AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST
30 PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
31 MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE

4 HOUSE BILL 813
1 PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN–STATE
2 COST–OF–DISPENSING SURVEY.
3 SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
4 measure, is necessary for the immediate preservation of the public health or safety, has
5 been passed by a yea and nay vote supported by three–fifths of all the members elected to
6 each of the two Houses of the General Assembly, and shall take effect from the date it is
7 enacted.
8 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
9 That the Maryland Insurance Administration and the Maryland Department of Health
10 shall:
11 (1) convene a workgroup of interested stakeholders, including community
12 pharmacies from both chain and independent settings, pharmacy services administrative
13 organizations, pharmacists, pharmacy benefits managers, and managed care organizations
14 and third–party experts in the field of drug pricing in Medicaid;
15 (2) review reimbursement for pharmacists, including:
16 (i) existing Maryland Medical Assistance Program requirements for
17 pharmacy benefits managers and managed care organizations related to dispensing fee
18 reimbursement, pharmacy benefits managers fees charged to pharmacies and the
19 Maryland Medical Assistance Program, transparency in pricing and reimbursement data,
20 specialty drug designations, and appeals processes;
21 (ii) how other states’ pharmacy benefits services operate in
22 Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;
23 (iii) measures that offset the Department’s costs to fund the Medicaid
24 Managed Care Program and adopt NADAC plus the Fee–for–Service Professional
25 Dispensing, including:
26 1. savings associated with NADAC ingredient cost pricing
27 and managed care organizations; and
28 2. pharmacy benefits managers administrative fee
29 consolidation and rebate allocations; and
30 (iv) strategies for adopting pharmacy reimbursement parity and
31 drug pricing transparency;
32 (3) review coverage requirements for specialty drugs, including:
33 (i) which drugs are considered specialty for purposes of formularies
34 across carriers and pharmacy benefits managers; and

HOUSE BILL 813 5
1 (ii) what these drugs have in common for purposes of developing a
2 new definition for “specialty drug”;
3 (4) review ERISA exemptions for pharmacy benefits management
4 regulation, including:
5 (i) the scope of Rutledge v. Pharmaceutical Care Management
6 Association and subsequent case law and federal guidance;
7 (ii) how other states have responded to the Rutledge decision; and
8 (iii) what, if any, other State laws should be amended;
9 (5) on or before December 31, 2025, submit an interim report on their
10 findings and recommendations to the Senate Finance Committee and the House Health
11 and Government Operations Committee, in accordance with § 2–1257 of the State
12 Government Article; and
13 (6) on or before December 31, 2026, submit a final report on their findings
14 and recommendations to the Senate Finance Committee and the House Health and
15 Government Operations Committee, in accordance with § 2–1257 of the State Government
16 Article.
17 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
18 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA    E 5   C P R R R S T A P P M W F M m a p o c p o l r p b m t i o D p d s B  A S  A  (]
[DELETED:  H  B  A S  A  ( B  A S  A  ( B  A S  A  (  S T A 1  ( ( Et ]S(  T  a p u p () o t s t P s]( e mmr l f t d p f w te, bt.    E()      S B A L E T T A V RA C– O O T G PTP T FEFRS   D F D B T E I NTTOFDS––    () If ]()[]E(X A P I P  O TN    s b b o t ct o t]NADAA V R C O b EFRS B T E I A W T M RNTTOFDS– .]
[DELETED: H 3    P()()        )  R      ) AI    )T§12IH    N R   . A 1  (  “ i t S E a R H a W B P,AR A N H S PN O A H M      () p] (   () e] ( t    “PR D N I A N H     ) O    )IPN      )IF     O A M C ON A D I   O T§1 –GA  E RE S R T P A A  A V R C OADA EFRS DHMM E E A E S ]
[DELETED:  H –S I A W T M R INTTOFD–   S m b e e  S T M s   ( c p o a   ( r    ( e p r p b m f c t p a t M s    ( h o s p b s o i M    ( m M C P a a N p t F P D     1 s a w N i c p a     2 p b m a f c    ( s f a p r p a d   ( r    ( w a]
[DELETED: H 5    ( w n   ( r E e f p b m r    ( t s o R v P C M A    ( h    ( w   ( o o b D 3 2 s a i r o t f a G O C i a w § 2 o t S G   ( o a r t t S F C a t H H a G A  S 1          G               ]